GABAB PAM
Substance Use Disorder
Key Facts
About Addex Therapeutics
Addex Therapeutics is a clinical-stage biotech focused on developing a new class of oral drugs—allosteric modulators—for neurological disorders. Its core achievement is building a robust pipeline of eight candidates, with lead programs in Phase 2/3 for Parkinson's disease dyskinesia (dipraglurant) and Phase 2 for epilepsy (ADX71149, partnered with Janssen). The company's strategy centers on advancing its proprietary GPCR modulation platform to create safer, more selective therapeutics, while pursuing strategic partnerships and funding to de-risk development and drive value.
View full company profileAbout Addex Therapeutics
Addex Therapeutics is a clinical-stage biotech focused on developing a new class of oral drugs—allosteric modulators—for neurological disorders. Its core achievement is building a robust pipeline of eight candidates, with lead programs in Phase 2/3 for Parkinson's disease dyskinesia (dipraglurant) and Phase 2 for epilepsy (ADX71149, partnered with Janssen). The company's strategy centers on advancing its proprietary GPCR modulation platform to create safer, more selective therapeutics, while pursuing strategic partnerships and funding to de-risk development and drive value.
View full company profileTherapeutic Areas
Other Substance Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| SUD Program | Ignite Biomedical | Discovery |